Before the availability of the implantable defibrillator, the cost of treating recurrent sustained ventricular tachycardia or ventricular fibrillation was already substantial. Several studies documented the costs of treatment at individual centers with and without electrophysiologic testing before the implantable defibrillator was widely used. These reports ranged from an average of approximately $12,000 in total hospital charges for empiric therapy at one center to an average of $42,000 per hospitalization for therapy guided by electrophysiologic testing at another institution.9- 1 The cost of all expensive innovations, including that of the implantable defibrillator, may be a cause of concern for insurers, hospitals, and for society in general. However, the appropriate concern is the incremental cost of the technology relative to its incremental benefit. To date, no one has thoroughly explored the relative cost effectiveness of the device. In this paper, we present the results of a study of the cost effectiveness of the implantable defibrillator with secondary data, expert opinion, and techniques of decision analysis. We also compare the cost effectiveness of the device with that of other life-saving interventions. With the exception of patients suffering operative or perioperative deaths, it was assumed that patients dying in any given year died, on average, at the midpoint of the year and that they consumed half of the health-care resources used by patients surviving the year. Patients dying within 30 days of receiving an implant were assumed to incur only the costs of the initial hospitalization for implantation, and in these cases, the effectiveness of the device was zero.
Methods
Cost-effectiveness ratios were calculated using mean estimates for all variables under two scenarios: a 1986 scenario, corresponding to a time when the device was relatively new, and a 1991 scenario, when it will be more widely used and its features refined. Sensitivity analyses spanning the entire range of estimates provided by the physicians were then conducted on all relevant variables under each of these two scenarios. Finally, all costs were inflated to 1986 dollars. Future health-care costs and life-years saved were discounted at a rate of 5%.26
Results

Data Elements
Resource use. Table 2 lists the mean value of the physicians' estimates for each category of research use. These were the values used in the baseline cost-effectiveness analysis described below.
Charges. Initial hospitalization costs for defibrillator implantation ($49,830) were obtained from HCFA, based on data collected from 138 patients. Repeat hospitalization costs for pulse generator or lead replacements ($17,810) were also obtained from data submitted to HCFA based on data collected from 65 patients. For the comparison group, an average total hospital charge of $13,680 was obtained from the MEDPAR data base and used for both initial and repeat hospitalizations.
Physician fees were estimated at $6,000 for procedures and visits during the initial hospitalization for the device group and $4,000 for procedures and visits during the initial hospitalization in the other group and for rehospitalizations in both groups.
The remaining outpatient charge estimates used in the analysis are summarized in Table 2 . These data were obtained from Medicare carriers and from pharmacies as previously described.
Effectiveness. Reported experience with the implantable defibrillator suggests an operative (less than 30 days after implantation) mortality rate of 3%, an arrhythmic mortality rate during the first year after implantation of 2%, and a total year-1 mortality rate (including operative deaths) of 14%.4,5,7-9 Based on these statistics, 0.03, 0.02, and 0.09 [0.14-(0.03+0.02)] were the figures derived and used as estimates of the probability of operative, arrhythmic, and other mortality, respectively, for a patient treated with the ,AC, total costs of defibrillator minus total costs of drug therapy; AE, effectiveness of defibrillator minus effectiveness of drug therapy, expressed in terms of life expectancy. *These estimates represent the extremes of the ranges provided by the expert panel. tThese figures represent data from one of our institutions (J.N.R., B.M.) on rehospitalization rates for 19 defibrillator recipients who have had a device implanted for at least 1 year. *This estimate was unanimous; all physicians provided the same figure. §These values represent the extremes of the ranges obtained from the literature. AC, total costs of defibrillator minus total costs of drug therapy; AE, effectiveness of defibrillator minus effectiveness of drug therapy, expressed in terms of life expectancy. *These estimates represent the extremes of the range provided by the expert panel.
tThese values represent the extremes of the range obtained from the literature.
also worsens the relative cost effectiveness of the device, in this case from $15,700 to $18,500 per life-year saved. We also simultaneously varied the 1-year and subsequent-years arrhythmic mortality rates of the defibrillator group from the recently reported value of 0.018 up to 0.04 and found that this changed the cost-effectiveness ratio from $16,600 to $19,700 per life-year saved. As expected, varying the initial hospitalization cost for device implantation from $45,000 to $52,000 causes the cost-effectiveness ratio to worsen, from approximately $14,800 to $18,600 per life-year saved. Correspondingly, varying the cost of the initial hospitalization in the nondefibrillator group from $12,000 to $42,000 -the range reported in the literatureresults in a decrease in the ratio from $18,300 to $2,300 per life-year saved.
Whereas expert opinion varied most on rehospitalization rates for the nondefibrillator group, a unanimous estimate for rehospitalization rates in the device group for the year after implantation was obtained (0.5 admissions per year). Thus, varying rehospitalization rates in the defibrillator group over the relevant range caused the ratio to change only from approximately $15,600 to $22,300, whereas varying rehospitalization rates for the nondefibrillator group caused the ratio to increase from $7,000 to $29,600
per life-year saved.
Finally, we tested the sensitivity of the model to changes in the likelihood that a patient who is treated with a defibrillator is also prescribed antiarrhythmic medication. Results of all these analyses are summarized in Table 5 With the base-case assumptions for this 1991 scenario, a figure of $7,400 per life-year saved, in 1986 dollars, was obtained. Sensitivity analyses on a number of variables were then conducted for the 1991 scenario, and it was discovered that, at best, the device may actually become cost saving. If the rehospitalization rate in the nondefibrillator group is between two and three admissions per year during the first year and one per year thereafter (reflecting in part the longer battery life expected of future devices), the defibrillator may decrease total costs for these patients, in addition to saving life-years. The worst case scenario, on the other hand, resulted in a cost-effectiveness ratio of $19,600 per life-year saved. 7, the cost effectiveness of the implantable defibrillator is well within the range of currently accepted life-saving technologies. The implantable defibrillator is clearly life saving; with the model described in this paper, this technology appears also to be cost effective when compared with other life-saving interventions. Moreover, as the technology develops in the future, it may even become cost saving. Increased pulse-generator longevity should decrease the frequency of pulse-generator replacement and rehospitalization, and earlier implantation, as well as elimination of the need for thoracotomy, should substantially decrease the cost of the initial hospitalization for defibrilator patients, thus improving the device's cost effectiveness. Moreover, pulse generator replacements are already being performed on an outpatient basis in some centers. As experience is gained with the implantable defibrillator, need for concomitant pharmacologic therapy may diminish, further enhancing its cost effectiveness and possibly the quality of life of surviving patients.
As has been stated, effectiveness in this study was expressed only in terms of mortality. It is likely, however, that patients receiving a defibrillator would experience a greater improvement in the quality of their ensuing life than would patients treated solely with drugs. Approximately 30% of patients treated with antiarrhythmic therapy experience adverse effects,28 which range from nausea and vomiting to significant cardiac or pulmonary problems, including exacerbation of arrhythmias. 29, 30 Patients treated with the defibrillator may benefit from the knowledge that they have an effective therapy continuously in place. However, they may also develop side effects of surgery as well as inappropriate device discharges, device failures, and psychologic reactions ranging from dependency on the device to fear of inappropriate (or appropriate) discharge. Limited data currently exist documenting and quantifying these outcomes31; therefore, quality adjustment was omitted from the analysis.
Although we feel confident that the cost effectiveness of the implantable defibrillator lies within the previously mentioned range, there are significant limitations of this study. First, the device was compared only to pharmacologic therapy; surgical intervention was omitted from analysis. Second, because of the lack of availability of some data, we relied on expert opinion for a number of important variables. To compensate for the lack of precision inherent in expert opinion, we varied the input parameters for the sensitivity analysis over the entire range of responses provided. Third, the MEDPAR data base was limited in its potential for identification of device candidates because no specific codes existed for electrophysiologic testing or out-of-hospital cardiac resuscitation at the time of this study. In addition, only Medicare patients are included, and because patient identifiers have been removed, multiple admissions cannot be tracked, and initial and subsequent hospitalizations cannot be differentiated.
Throughout the analysis, we sought always to opt for the more conservative approach, biasing our assumptions against the defibrillator and in favor of treatment without the device. For example, as stated, because initial and subsequent hospitalizations cannot be distinguished in the MEDPAR data base, we calculated an average charge across all admissions. In doing so, it is likely that we underestimated the initial hospitalization costs for the nondefibrillator group. Moreover, drug-refractory patients cannot be discerned in this data base, further increasing the likelihood of underestimation of hospitalization costs in the comparison group. Published reports of the hospital costs associated with electrophysiologic evaluation of ventricular arrhythmia patients suggest that initial hospitalization costs may be as high as $42,000.1" The use of that figure for the initial hospitalization costs for the comparison group and the MEDPAR figure ($13,700) for subsequent hospitalizations resulted in a cost-effectiveness ratio of $2,300 per life-year saved. This may be more representative of the cost effectiveness of the device when it is used in the drug-refractory patient.
In the sensitivity analyses, we varied input parameters over the entire range of estimates provided, even when we believed that an extreme value provided was unlikely to be an accurate representation of patient management in general. In the 1991 scenario, we used hospitalization charges equivalent to those for the 1986 scenario, although elimination of the need for a thoracotomy, earlier decision making, and a lessened need for prolonged serial drug testing before implantation would likely result in a significantly shorter length of stay for implantation and hence a substantially lower charge. Because unforeseen costs could arise, we elected to use the cost estimate for initial hospitalization in the 1986 scenario rather than lowering that cost to reflect expected decreases in resource use associated with the hospitalization for initial implantation in 1991. Moreover, given the advent of pulse-generator longevities of 5 years, we used what we believe to be a conservative estimate (every 2 years) of rehospitalization frequency for the defibrillator group in subsequent years. Despite these conservative estimates and assumptions, however, the implantable defibrillator, when used in the high-risk patient, still appears to provide a cost-effective therapy relative to other cost-increasing, life-saving therapies.
